Management of Controversial Gastroenteropancreatic (GEP) Neuroendocrine Tumour (NET) Clinical Situations (CS) with Somatostatin Analogues (SSAs): Results of a Delphi Questionnaire (Q) Panel from the NETPraxis Program

#1343

Introduction: In NET CS where use of SSAs is controversial due to lack of evidence, clinical experience and expert opinion can help establish recommendations.

Aim(s): The NETPraxis program aims to develop a common guidance for controversial CS with SSAs in clinical practice in Spain.

Materials and methods: 5 CS were defined with a common core (non-functioning NET, not susceptible of surgery/locoregional therapy, Ki67<10% [except CS5], ECOG≤2), and tailored questions on the use of SSAs (CS1: enteropancreatic origin, nonprogressive <6 mo; observation or SSA? CS2: pancreatic origin; initial SSA, molecularly targeted therapy (MTT) or chemotherapy? CS3: GEP-NET progressing with SSA; maintain SSA? CS4: GEP-NET, negative octreoscan; initial SSA? CS5: GEP-NET, Ki67>10%, positive octreoscan; initial SSA?). Management of CS was discussed with Spanish oncologists, followed by a 48-item Delphi Q with a 9-point rating scale (9=full agreement; consensus >2/3 of responses in the same tertile).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Sevilla I

Authors: Sevilla I, Segura A, Capdevila J, Lopez C, Garcia Carbonero R,

Keywords: SSA, Delphi, NETPraxis,

To read the full abstract, please log into your ENETS Member account.